Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
06/2002
06/26/2002EP1216257A1 Compounds for the treatment of ischemia
06/26/2002EP1216248A2 Triazolopyrimidine derivatives
06/26/2002EP1216246A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
06/26/2002EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
06/26/2002EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
06/26/2002EP1216067A1 Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation
06/26/2002EP1216045A2 Vasopressin agonist formulation and process
06/26/2002EP1216037A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
06/26/2002EP0820441B1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
06/26/2002CN1355811A Integrain receptor antagaonists
06/26/2002CN1355801A Thiazolidinedione derivative and its use as antidiabetic
06/26/2002CN1355799A 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
06/26/2002CN1355047A Process for preapring compounds clemetis medicine
06/25/2002US6410802 Etherification in presence of base
06/25/2002US6410790 Analgesics
06/25/2002US6410589 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
06/25/2002US6410564 Naphthyl compounds, intermediates, processes, compositions, and methods
06/25/2002US6410552 Benzoether and related compositions and methods
06/25/2002US6410551 Bronchodilator
06/25/2002US6410540 Inhibitors of p38-αkinase
06/25/2002US6410534 Anticancer agents
06/25/2002US6410532 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
06/25/2002US6410320 Kidney stem cells; for use in treatment of kidney defects
06/20/2002WO2002048337A2 Secreted human proteins
06/20/2002WO2002048163A2 PROCESSES FOR THE PREPARATION OF αGAL(1→4)βGAL(1→4)GLC-OR TRISACCHARIDES
06/20/2002WO2002048148A2 Pyrazolopyridine derivatives
06/20/2002WO2002048134A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
06/20/2002WO2002048124A2 Piperazine derivatives
06/20/2002WO2002048114A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002WO2002048112A2 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone
06/20/2002WO2002048107A1 Antitumoral carbazoles
06/20/2002WO2002047722A1 Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
06/20/2002WO2002047719A2 Survical promoting ncam binding and ncam ligand biding compounds
06/20/2002WO2002047713A2 Composition containing a mixture of growth factor for the treatment of renal injury
06/20/2002WO2002047711A2 Modulators of activity of g-protein-coupled receptor kinases
06/20/2002WO2002047708A2 Selective cox-2 inhibition from edible plant extracts
06/20/2002WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
06/20/2002WO2002047692A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
06/20/2002WO2002047685A2 Nmda receptor agonist pharmaceutical compositions
06/20/2002WO2002047679A2 Nonpeptide agonists and antagonists of vasopressin receptors
06/20/2002WO2002047676A1 Topical composition and method for treating urinary stress incontinence
06/20/2002WO2002040019A8 Benzimidazole derivatives
06/20/2002WO2002016436A3 ANTIBODIES TO HUMAN IL-1$g(b)
06/20/2002WO2001085942A3 Cytoskeleton-associated proteins
06/20/2002WO2001077164A3 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
06/20/2002WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
06/20/2002WO2001052837A3 Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
06/20/2002WO2000067734A3 Use of phthalazine derivatives
06/20/2002WO2000061750A9 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
06/20/2002US20020077476 Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
06/20/2002US20020077356 Nonsteroidal antiinflammatory agents
06/20/2002US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis
06/20/2002US20020077319 Combination of GABA agonists and aldose reductase inhibitors
06/20/2002US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder
06/20/2002US20020076796 2786, a novel human aminopeptidase
06/20/2002US20020076766 Novel glucosaminidase
06/20/2002US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain
06/20/2002US20020076416 Chimeric peptide immunogens
06/20/2002DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane
06/20/2002DE10060809A1 Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker Substituted anthranilic acids, their use as a medicament or diagnostic, and she containing drug, as well as a pharmaceutical combination preparation with a sodium / hydrogen exchange (NHE) blockers
06/20/2002DE10060292A1 Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibiting the Na + / H + exchanger and containing medicament
06/20/2002DE10059413A1 Verwendung von substituierten 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for the therapy of urinary incontinence
06/20/2002CA2446832A1 Method of treating renal injury
06/20/2002CA2432825A1 Nonpeptide agonists and antagonists of vasopressin receptors
06/20/2002CA2431172A1 Nmda receptor antagonist pharmaceutical compositions
06/20/2002CA2431107A1 Antitumoral carbazoles
06/20/2002CA2430992A1 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
06/20/2002CA2430151A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002CA2428216A1 Secreted proteins
06/19/2002EP1215214A1 Novel polypeptide
06/19/2002EP1215207A2 Salts of isoleucyl-thiazolidine and -pyrrolidine and their use as dipeptidylpeptidase inhibitors
06/19/2002EP1215203A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
06/19/2002EP1214936A2 Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents
06/19/2002EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
06/19/2002EP1214422A1 Phosphatases which activate map kinase pathways
06/19/2002EP1214404A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
06/19/2002EP1214401A2 Dna encoding the human serine protease c-e
06/19/2002EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic
06/19/2002EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies
06/19/2002EP1214337A2 Proteins associated with cell differentiation
06/19/2002EP1214335A1 Gamma-carboxyglutamate containing conopeptides
06/19/2002EP1214326A1 Inhibitors of prenyl-protein transferase
06/19/2002EP1214323A1 Indoloazepines as vasopressin receptor antagonists
06/19/2002EP1214318A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
06/19/2002EP1214313A2 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same
06/19/2002EP1214312A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles
06/19/2002EP1214303A1 Heterocyclic compounds and methods of use thereof
06/19/2002EP1214291A1 Biphenyl derivatives used as nhe-3 inhibitors
06/19/2002EP1214096A2 Taxane prodrugs
06/19/2002EP1214091A1 Therapies for chronic renal failure using one or more integrin antagonists
06/19/2002EP1214089A1 Therapeutic uses of m3 polypeptide
06/19/2002EP1214039A2 Methods and compositions for preventing and treating urinary tract disorders
06/19/2002EP1214038A2 Methods and compositions for preventing and treating prostate disorders
06/19/2002EP0975623B1 Indazole amide compounds as serotoninergic agents
06/19/2002EP0866691B1 Sublingual and buccal administration of selegiline
06/19/2002EP0772450B1 Methods for treating bleeding disorders
06/19/2002CN1354737A Novel derivatives of 3-3-diphenylpropylamines
06/19/2002CN1354013A Compound Chinese medicine tea bag for curing acute and chronic urethritis, and its preparing method
06/18/2002US6407114 Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
06/18/2002US6407101 Progesterone receptor antagonists; contraceptives, hormone replacement therapy; breast and prostate cancer treatment; menopause